Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Oryzon Genomics (ORY SM)
Watchlist
54
Analysis
Health Care
•
Spain
Oryzon Genomics, SA is a clinical stage biopharmaceutical company that develops epigenetics-based therapeutics.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Oryzon Genomics
•
10 Jun 2022 16:28
•
Issuer-paid
Oryzon Genomics - Continued positive responses in ALICE trial
Oryzon presented a 42-month update of its ongoing Phase IIa ALICE trial for the treatment of acute myeloid leukaemia (AML) in newly diagnosed...
Edison Investment Research
Follow
674 Views
Share
bullish
•
Oryzon Genomics
•
09 Jun 2022 20:32
•
Issuer-paid
Oryzon Genomics - FRIDA funding and orphan drug designation
Oryzon Genomics has been awarded a $2m public grant to support its ongoing Phase Ib FRIDA clinical study. This follows recent FDA approval of its...
Edison Investment Research
Follow
672 Views
Share
bullish
•
Oryzon Genomics
•
09 Feb 2022 20:12
•
Issuer-paid
Oryzon Genomics - Planning iadademstat’s path to market
Oryzon is making progress with its two epigenetic drugs, iadademstat for oncology and vafidemstat for CNS indications (both are lysine-specific...
Edison Investment Research
Follow
1.1k Views
Share
bullish
•
Oryzon Genomics
•
15 Jun 2021 20:04
•
Issuer-paid
Oryzon Genomics - Large response benefit consistent in ALICE trial
On 11 June 2021, Oryzon presented an updated set of data from the Phase IIa ALICE trial in acute myeloid leukaemia (AML) at the virtual Congress of...
Edison Investment Research
Follow
910 Views
Share
bullish
•
Oryzon Genomics
•
28 Sep 2020 17:51
•
Issuer-paid
Oryzon Genomics - Final update from Phase IIa CLEPSIDRA trial
On 17 September Oryzon presented an update from its Phase IIa CLEPSIDRA trial with iadademstat, a selective LSD1 inhibitor, in combination with...
Edison Investment Research
Follow
170 Views
Share
First
Previous
5
6
7
8
9
10
11
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x